{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:40:35Z","timestamp":1792233635445,"version":"4.4.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xphs.2026.104537","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:09:10Z","timestamp":1791644950000},"page":"104537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are we selecting the right model compounds for advanced formulation research?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-9696","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Solymosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4489-2001","authenticated-orcid":false,"given":"Dalip","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Alberto","family":"Afonso Urich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"H\u00f6rmann-Kincses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-3607","authenticated-orcid":false,"given":"Martin","family":"Spoerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Khinast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0001","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0002","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1208\/s12248-017-0085-5","article-title":"Evolution of choice of solubility and dissolution media after two decades of biopharmaceutical classification system","volume":"19","author":"Bou-Chacra","year":"2017","journal-title":"AAPS Journal"},{"issue":"12","key":"10.1016\/j.xphs.2026.104537_bib0003","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The Developability Classification System: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104537_bib0004","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1007\/s11095-012-0815-4","article-title":"Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS","volume":"29","author":"Charkoftaki","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2026.104537_bib0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijpharm.2019.05.041","article-title":"The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): beyond guidelines","volume":"566","author":"Charalabidis","year":"2019","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0006","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp0600182","article-title":"A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan","volume":"3","author":"Takagi","year":"2006","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104537_bib0007","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1021\/ed1003806","article-title":"A graphical journey of innovative organic architectures that have improved our lives","volume":"87","author":"McGrath","year":"2010","journal-title":"J Chem Educ"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1208\/s12248-025-01016-x","article-title":"Gastrointestinal bile salt concentrations in healthy adults under fasted and fed conditions: a systematic review and meta-analysis for mechanistic physiologically-based pharmacokinetic (PBPK) modelling","volume":"27","author":"Santos","year":"2025","journal-title":"AAPS J"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104537_bib0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2010.05.003","article-title":"Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon","volume":"395","author":"Pinto","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104537_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejps.2019.04.013","article-title":"Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: an UNGAP review","volume":"134","author":"Vertzoni","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0011","series-title":"Development, Preclinical Evaluation and First-in-Human Clinical Trial of a Nano-Amorphous Abiraterone Acetate Formulation","author":"Solymosi","year":"2019"},{"key":"10.1016\/j.xphs.2026.104537_bib0012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-026-01407-5","article-title":"The expanding role of formulations to enable oral delivery of poorly water-soluble drugs","volume":"25","author":"Ueda","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xphs.2026.104537_bib0013","article-title":"Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023","volume":"7","author":"Moseson","year":"2024","journal-title":"Int J Pharm X"},{"issue":"11","key":"10.1016\/j.xphs.2026.104537_bib0014","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J Pharmacy Pharmacol"},{"key":"10.1016\/j.xphs.2026.104537_bib0015","unstructured":"Benet LL, Wu CY Using a biopharmaceutics drug disposition classification system to predict bioavailability and elimination characteristics of new molecular entities NJDMDG. Preprint posted online August 5, 2006."},{"issue":"10","key":"10.1016\/j.xphs.2026.104537_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40261-015-0320-8","article-title":"Pharmacokinetics and bioavailability of a fixed-dose combination of ibuprofen and paracetamol after intravenous and oral administration","volume":"35","author":"Atkinson","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.xphs.2026.104537_bib0026","series-title":"Sporanox Capsules Prescribing Information","year":"2026"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0027","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.xphs.2021.02.019","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: carbamazepine","volume":"110","author":"Garc\u00eda","year":"2021","journal-title":"J Pharm Sci"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2026.104537_bib0028","article-title":"A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012","volume":"18","author":"Tolou-Ghamari","year":"2013","journal-title":"J Res Med Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2165\/00003088-199732040-00002","article-title":"Clinical pharmacokinetics of naproxen","volume":"32","author":"Davies","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00003088-198106040-00001","article-title":"Clinical pharmacokinetics of indomethacin","volume":"6","author":"Helleberg","year":"1981","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0031","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01063617","article-title":"Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man","volume":"4","author":"Kwan","year":"1976","journal-title":"J Pharmacokinet Biopharm"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136618","article-title":"Paracetamol as a post prandial marker for gastric emptying, a food-drug interaction on absorption","volume":"10","author":"Bartholom\u00e9","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-198207020-00001","article-title":"Clinical pharmacokinetics of paracetamol","volume":"7","author":"Forrest","year":"1982","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jps.20477","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol)","volume":"95","author":"Kalantzi","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0035","series-title":"Antara Capsule Prescribing Information","year":"2025"},{"issue":"10","key":"10.1016\/j.xphs.2026.104537_bib0036","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/jps.23233","article-title":"Biowaiver monographs for immediate-release solid oral dosage forms: Ketoprofen\u2020","volume":"101","author":"Shohin","year":"2012","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.1983.tb02152.x","article-title":"Absorption of orally administered amphotericin B lozenges","volume":"16","author":"Ching","year":"1983","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0038","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(24)29580-X","article-title":"Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption","volume":"297","author":"Paulson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"6B","key":"10.1016\/j.xphs.2026.104537_bib0039","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0002-9343(87)90630-9","article-title":"Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine","volume":"83","author":"Chung","year":"1987","journal-title":"Am J Med"},{"issue":"4 Pt 2","key":"10.1016\/j.xphs.2026.104537_bib0040","first-page":"18","article-title":"Pharmacokinetics and metabolism of nifedipine","volume":"5","author":"Raemsch","year":"1983","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.xphs.2026.104537_bib0041","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s11095-023-03624-8","article-title":"Small is powerful: demonstration of the impact of nanoformed piroxicam in a controlled clinical study","volume":"40","author":"Lakio","year":"2023","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2026.104537_bib0042","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/bph.14203","article-title":"Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s","volume":"175","author":"Lindmark","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0043","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Heykants3 AJ. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2026.104537_bib0044","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2018.01.009","article-title":"Development and applications of a physiologically-based model of paediatric oral drug absorption","volume":"115","author":"Johnson","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0045","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/jps.2600600919","article-title":"Absorption characteristics of solid dispersed and micronized griseofulvin in man","volume":"60","author":"Chiou","year":"1971","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0046","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jps.2600570613","article-title":"Absorption kinetics of griseofulvin in man","volume":"57","author":"Rowland","year":"1968","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2026.104537_bib0047","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/bcp.14684","article-title":"Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: a physiologically based pharmacokinetic\/pharmacodynamic analysis","volume":"87","author":"Niu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0048","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2125.1995.tb05722.x","article-title":"Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion","volume":"39","author":"Trull","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0049","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/bdd.347","article-title":"Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast & Zocor) in healthy human volunteers","volume":"24","author":"Najib","year":"2003","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00003088-199324030-00002","article-title":"Clinical pharmacokinetics and practical applications of Simvastatin","volume":"24","author":"Mauro","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0051","first-page":"30","article-title":"Bioequivalence study of two formulations of simvastatin 20 mg tablet in healthy Filipino participants under fasting conditions: a randomized, open-label, two-way crossover study","volume":"58","author":"Alvero","year":"2024","journal-title":"Acta Med Philipp"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0052","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12793\/tcp.2017.25.1.10","article-title":"Comparative pharmacokinetic and tolerability evaluation of two simvastatin 20 mg formulations in healthy Korean male volunteers","volume":"25","author":"Moon","year":"2017","journal-title":"Transl Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0053","first-page":"51","article-title":"Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers","volume":"6","author":"Nagelschmitz","year":"2014","journal-title":"Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0054","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00611905","article-title":"Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms","volume":"14","author":"Bogentoft","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00544245","article-title":"Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker","volume":"33","author":"V M\u00f6llendorff","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0056","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40262-015-0253-7","article-title":"A physiologically based pharmacokinetic drug\u2013Disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows","volume":"54","author":"Rasool","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"3B","key":"10.1016\/j.xphs.2026.104537_bib0057","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(88)90346-4","article-title":"Pharmacokinetics of lisinopril","volume":"85","author":"Beermann","year":"1988","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0058","first-page":"659","article-title":"Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor","volume":"7","author":"Nobel","year":"1988","journal-title":"Clin Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0016","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","article-title":"A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity","volume":"32","author":"Conaghan","year":"2012","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0017","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0950-3579(88)80019-0","article-title":"Pharmacokinetics of non-steroidal anti-inflammatory drugs","volume":"2","author":"Day","year":"1988","journal-title":"Baillieres Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00003088-198308040-00003","article-title":"Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs","volume":"8","author":"Verbeeck","year":"1983","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0019","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1023\/A:1018947113238","article-title":"Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model","volume":"10","author":"Oh","year":"1993","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/pharmaceutics12060493","article-title":"Intrinsic dissolution rate profiling of poorly water-soluble compounds in biorelevant dissolution Media","volume":"12","author":"Teleki","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0021","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1208\/s12248-010-9176-2","article-title":"Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus caco-2 monolayers","volume":"12","author":"Teksin","year":"2010","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10717544.2016.1225852","article-title":"Design of amphotericin B oral formulation for antifungal therapy","volume":"24","author":"Liu","year":"2017","journal-title":"Drug Deliv"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0023","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/bdd.2336","article-title":"Intestinal absorption pathways of lisinopril: mechanistic investigations","volume":"43","author":"Elewa","year":"2022","journal-title":"Biopharm Drug Dispos"},{"issue":"3B","key":"10.1016\/j.xphs.2026.104537_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(88)90346-4","article-title":"Pharmacokinetics of lisinopril","volume":"85","author":"Beermann","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.xphs.2026.104537_bib0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.17159\/0379-4350\/2019\/v72a33","article-title":"Structural characterization and thermal properties of the anti-malarial drug: lumefantrine","volume":"72","author":"Pansuriya","year":"2019","journal-title":"South Afr J Chem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0111","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/acs.molpharmaceut.1c00481","article-title":"Balancing solid-State stability and dissolution performance of lumefantrine amorphous solid dispersions: the role of polymer choice and drug\u2013Polymer interactions","volume":"19","author":"Hiew","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104537_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2026.126739","article-title":"Development of amorphous solid dispersion of delamanid, an extremely water-insoluble drug, by hot melt extrusion applying acid-base supersolubilization (ABS) principle","volume":"694","author":"Raje","year":"2026","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0070","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.xphs.2020.12.039","article-title":"Exploring the impact of intestinal fluid components on the solubility and supersaturation of Danazol","volume":"110","author":"Madsen","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0113","doi-asserted-by":"crossref","unstructured":"Childs SL, Kandi P, Lingireddy SR Formulation of a Danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. doi:10.1021\/mp400176y","DOI":"10.1021\/mp400176y"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0114","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1021\/mp500201s","article-title":"Impact of polymers on the precipitation behavior of highly supersaturated aqueous danazol solutions","volume":"11","author":"Jackson","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104537_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.mseb.2023.116351","article-title":"Molecular spectroscopy and optical effect of albendazole chemical compound behaves as liquid crystal: a theoretical and experimental approach","volume":"291","author":"Roy","year":"2023","journal-title":"Mater Sci Eng B"},{"issue":"15","key":"10.1016\/j.xphs.2026.104537_bib0116","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.3390\/molecules29153571","article-title":"Improving the solubility, stability, and bioavailability of albendazole through synthetic salts","volume":"29","author":"Yan","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2026.104537_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2026.127063","article-title":"Formulation of amorphous solid dispersion of clofazimine, an extremely water-insoluble basic drug, via hot-melt extrusion by applying acid-base supersolubilization principle","volume":"700","author":"Kathawala","year":"2026","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103782","article-title":"Highly increasing solubility of clofazimine, an extremely water-insoluble basic drug, in lipid-based SEDDS using digestion products of long-chain lipids","volume":"114","author":"Kandagatla","year":"2025","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106447","article-title":"The polymorph landscape of dabigatran etexilate mesylate: taking the challenge to bring a metastable polymorph to market","volume":"186","author":"Sieger","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104537_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2026.104487","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: dabigatran etexilate","volume":"115","author":"Niino","year":"2026","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1211\/jpp.58.6.0011","article-title":"Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone","volume":"58","author":"Sek","year":"2006","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0121","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10973-010-0685-0","article-title":"Thermal and structural characterization of two polymorphs of Atovaquone and of its chloro derivative","volume":"102","author":"Malpezzi","year":"2010","journal-title":"J Therm Anal Calorim"},{"issue":"35","key":"10.1016\/j.xphs.2026.104537_bib0122","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1039\/D0CE00952K","article-title":"A novel lurasidone hydrochloride\u2013shikimic acid co-amorphous system formed by hydrogen-bonding interaction with the retained pH-dependent solubility behavior","volume":"22","author":"Hu","year":"2020","journal-title":"CrystEngComm"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0123","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12247-025-10129-x","article-title":"Enhancement of lurasidone hydrochloride dissolution and pharmacodynamic properties via Co-crystal and eutectic formation","volume":"20","author":"Hussien","year":"2025","journal-title":"J Pharm Innov"},{"issue":"13","key":"10.1016\/j.xphs.2026.104537_bib0124","first-page":"2905","article-title":"Suitability assessment of Lurasidone hydrochloride for sustained release injectable microsphere formulation by preformulation studies","volume":"20","author":"Patel","year":"2022","journal-title":"Neuro Quantol"},{"key":"10.1016\/j.xphs.2026.104537_bib0125","doi-asserted-by":"crossref","first-page":"13857","DOI":"10.2147\/IJN.S494083","article-title":"Comparison of solid self-nanoemulsifying systems and surface-coated microspheres: improving oral bioavailability of niclosamide","volume":"19","author":"Baek","year":"2024","journal-title":"Int J Nanomed"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104537_bib0126","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2017.06.007","article-title":"Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems","volume":"528","author":"Pardhi","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104537_bib0127","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejps.2018.01.039","article-title":"Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): an in vitro-in silico-in vivo approach","volume":"115","author":"Hens","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2026.104537_bib0128","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1021\/acs.molpharmaceut.0c00471","article-title":"Novel high-drug-loaded amorphous dispersion tablets of posaconazole; In vivo and In vitro assessment","volume":"17","author":"Mudie","year":"2020","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26868","article-title":"Nanoparticle based formulation of dihydroartemisinin-lumefantrine duo-drugs: preclinical evaluation and enhanced antimalarial efficacy in a mouse model","volume":"10","author":"Odera","year":"2024","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.xphs.2026.104537_bib0060","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.xphs.2023.04.003","article-title":"Formulation and scale-up of fast-dissolving lumefantrine nanoparticles for oral malaria therapy","volume":"112","author":"Armstrong","year":"2023","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0061","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1473-3099(23)00231-1","article-title":"Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout","volume":"23","author":"Chen","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0062","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.xphs.2020.12.033","article-title":"(Tony). Physical stability and dissolution of lumefantrine amorphous solid dispersions produced by spray anti-solvent precipitation","volume":"110","author":"Bhujbal","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122354","article-title":"Lumefantrine solid dispersions with piperine for the enhancement of solubility, bioavailability and anti-parasite activity","volume":"628","author":"Takale","year":"2022","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0064","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00868-17","article-title":"Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach, an outcome from a randomized, open-label pharmacokinetic study in healthy volunteers","volume":"61","author":"Jain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0065","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","article-title":"Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria","volume":"44","author":"Ezzet","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2026.104537_bib0066","series-title":"Deltyba Assessment Report","year":"2013"},{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0067","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0976-500X.136121","article-title":"A new armor in combating drug-resistant tuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"issue":"23","key":"10.1016\/j.xphs.2026.104537_bib0068","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0069","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003495-198019050-00001","article-title":"Pharmacology and pharmacokinetics of danazol","volume":"19","author":"Potts","year":"1980","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0071","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/j.1552-4604.1993.tb04673.x","article-title":"Effect of food and a monoglyceride emulsion formulation on danazol bioavailability","volume":"33","author":"Charman","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2026.104537_bib0072","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejpb.2019.05.024","article-title":"Danazol oral absorption modelling in the fasted dog: an example of mechanistic understanding of formulation effects on drug pharmacokinetics","volume":"141","author":"Pade","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"10.1016\/j.xphs.2026.104537_bib0073","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1021\/mp400176y","article-title":"Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability","volume":"10","author":"Childs","year":"2013","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2026.104537_bib0074","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1002\/jps.23667","article-title":"Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs","volume":"102","author":"Devalapally","year":"2013","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0075","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10717544.2013.869275","article-title":"Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds","volume":"22","author":"Devalapally","year":"2015","journal-title":"Drug Deliv"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0076","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/03639040500529176","article-title":"Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies","volume":"32","author":"Vaughn","year":"2006","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2026.104537_bib0077","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/jps.10163","article-title":"Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 beta-cyclodextrin (SBE 7) complexes","volume":"91","author":"Jain","year":"2002","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104537_bib0078","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/bdd.327","article-title":"Dose dependent pharmacokinetics of albendazole in human","volume":"23","author":"Mirfazaelian","year":"2002","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0079","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/BF00608219","article-title":"Pharmacokinetics of albendazole in man","volume":"30","author":"Marriner","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.xphs.2026.104537_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010497","article-title":"Factors associated with variation in single-dose albendazole pharmacokinetics: a systematic review and modelling analysis","volume":"16","author":"Whittaker","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"20","key":"10.1016\/j.xphs.2026.104537_bib0081","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.3390\/cancers16203454","article-title":"From deworming to cancer therapy: benzimidazoles in hematological malignancies","volume":"16","author":"Golla","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.xphs.2026.104537_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118189","article-title":"Drug repurposing and relabeling for cancer therapy: emerging benzimidazole antihelminthics with potent anticancer effects","volume":"378","author":"Nath","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115539","article-title":"Clofazimine: a journey of a drug","volume":"167","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.xphs.2026.104537_bib0084","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","article-title":"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid","volume":"84","author":"Nix","year":"2004","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2165\/00003088-198916020-00002","article-title":"Clinical pharmacokinetics of Clofazimine: a review","volume":"16","author":"Holdiness","year":"1989","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2026.104537_bib0086","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01560-21","article-title":"Pharmacokinetics and pharmacodynamics of Clofazimine for treatment of cryptosporidiosis","volume":"66","author":"Zhang","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0087","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.xphs.2026.104537_bib0088","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.xphs.2026.104537_bib0089","series-title":"Pradaxa Prescribing Information","year":"2025"},{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/psp4.12589","article-title":"Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate","volume":"10","author":"Farhan","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2026.104537_bib0091","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2147\/DDDT.S203112","article-title":"Dabigatran must be used carefully: literature review and recommendations for management of adverse events","volume":"Volume 13","author":"Lin","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0092","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2169\/internalmedicine.1618-18","article-title":"Dabigatran-induced esophageal ulcer at a natural constriction","volume":"58","author":"Sasaki","year":"2019","journal-title":"Internal Med"},{"key":"10.1016\/j.xphs.2026.104537_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227401","article-title":"Oral ulcer due to dabigatran capsule","volume":"2018","author":"Kuno","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.xphs.2026.104537_bib0094","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40256-019-00377-x","article-title":"Bioequivalence of a newly developed Dabigatran Etexilate tablet versus the commercial capsule and impact of rabeprazole-induced elevated gastric pH on exposure in healthy subjects","volume":"20","author":"Harada","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.xphs.2026.104537_bib0095","series-title":"Mepron Prescribing Information","year":"2008"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0096","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/nnm.13.61","article-title":"Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria","volume":"9","author":"Borhade","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.xphs.2026.104537_bib0097","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejps.2017.09.051","article-title":"Atovaquone oral bioavailability enhancement using electrospraying technology","volume":"111","author":"Darade","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104537_bib0098","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejps.2016.03.005","article-title":"Bioavailability enhancement of atovaquone using hot melt extrusion technology","volume":"86","author":"Kate","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0099","first-page":"989","article-title":"Solid lipid nanoparticles of Atovaquone based on 2(4) full-factorial design","volume":"14","author":"Mohtar","year":"2015","journal-title":"Iran J Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2026.104537_bib0101","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/cancers15041344","article-title":"Repurposing Atovaquone as a therapeutic against acute myeloid leukemia (AML): combination with conventional chemotherapy is feasible and well tolerated","volume":"15","author":"Stevens","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xphs.2026.104537_bib0102","series-title":"Latuda Assessment Report","year":"2014"},{"issue":"5","key":"10.1016\/j.xphs.2026.104537_bib0103","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1208\/s12249-015-0449-z","article-title":"Optimization, and evaluation of lurasidone hydrochloride nanocrystals","volume":"17","author":"Shah","year":"2016","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.xphs.2026.104537_bib0104","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3109\/03639045.2015.1118496","article-title":"Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state","volume":"42","author":"Miao","year":"2016","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/adt.2023.089","article-title":"Optimization of Lurasidone HCl-loaded PLGA nanoparticles for intramuscular delivery: enhanced bioavailability, reduced dosing frequency, pharmacokinetics, and therapeutic outcomes","volume":"22","author":"Macwan","year":"2024","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.xphs.2026.104537_bib0106","article-title":"The challenge of repurposing niclosamide: considering pharmacokinetic parameters, routes of administration, and drug metabolism","volume":"81","author":"Jara","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2026.104537_bib0107","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.2147\/DDDT.S473178","article-title":"Revisiting niclosamide formulation approaches \u2013 a pathway toward drug repositioning","volume":"18","author":"Jug","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.xphs.2026.104537_bib0108","series-title":"Noxafil Prescribing Information","year":"2026"},{"issue":"2","key":"10.1016\/j.xphs.2026.104537_bib0109","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ajt.14580","article-title":"Salvage therapy with topical posaconazole in lung transplant recipients with invasive scedosporium infection","volume":"18","author":"Sol\u00e9","year":"2018","journal-title":"Am J Transplant"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:41:58Z","timestamp":1792230118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":128,"alternative-id":["S0022354926003874"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104537","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are we selecting the right model compounds for advanced formulation research?","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104537"}}